Pharma > Pharma Communications to Healthcare Professionals
PUBLICIS LIFE BRANDS RESOLUTE, London / ABBOTT / 2017
Overview
Credits
Audience
Cardiologists, Endocrinologists and GPs
BriefExplanation
BriefWithProjectedOutcomes
All content regarding the disease or patient opinion had to be medically accurate and fully substantiated.
EntrySummary
Treatment and control of dyslipidaemia is needed to reduce or prevent the risk of cardiovascular (CV) disease. Statins reduce CV risk but type 2 diabetes (T2D) patients with increased triglycerides (TGs) and low HDL-C still have a substantial residual risk. Lipanthyl, a fenofibrate, is used to lower triglycerides and lower CV risk. Research suggests that both a statin and a fenofibrate are necessary for adequate CV protection in these patients.
More Entries from Prescription - Branded Communication in Pharma
24 items
More Entries from PUBLICIS LIFE BRANDS RESOLUTE
24 items